

SUPPLEMENT

Bodrova V.V., Shustova O.N., Golubeva N.V., Alieva A.K., Vlodyanovsky V.V., Pevzner D.V., Mazurov A.V. (2024) Assessment of platelet functional activity in healthy individuals and patients receiving antiplatelet therapy. Possible inconsistencies between aggregation and flow cytometry tests. Biomeditsinskaya Khimiya, 70(2), 99-108.

DOI: 10.18097/PBMC20247002099




Figure S1. Examples of interactions between LTA and flow cytometry indexes of platelet activation in HV group. (A) TRAP 1 μM , Vmax versus PAC-1, %. (B). ADP 2.5 μM , Tmax versus CD62P, %. (C) TRAP 10 μM , Tmax versus PAC-1, %. (D) ADP 20 μM , Tmax versus CD62P, %. r – Coefficient of correlation. Examples of high/moderate (A, B) and low/no correlations (C, D).




Figure S2. Examples of interactions between LTA and flow cytometry indexes of platelet activation in SA group (ASA + clopidogrel) and ACS group (ASA + ticagrelor). (A) SA group, ADP 20 μ M, Tmax versus PAC-1, %. (B). ACS group, ADP 20 μ M, Tmax versus PAC-1, MFI. (C) ACS group TRAP 10 μ M, Tmax versus PAC-1, %. (D) ACS group, TRAP 10 μ M, Tmax versus CD62P, %. r – Coefficient of correlation. Examples of high/moderate (A, B) and low/no correlations (C, D).




Figure S3. Examples of interactions between flow cytometry indexes of platelet activation in HV, SA (ASA + clopidogrel) and ACS (ASA + ticagrelor) patients. (A) HV group, TRAP 1 μ M, PAC-1, % versus CD62P, %. (B) HV, ADP 2.5 μ M, PAC-1, % versus CD62P, %. (C) SA group (ASA + clopidogrel), ADP 20 μ M, PAC-1, % versus CD62P, %. (D) ACS group (ASA + ticagrelor), ADP 5 μ M, % versus CD62P, %. r – Coefficient of correlation. Examples of high/moderate (A, C) and low/no correlations (B, D).